MedPath
FDA Approval

Ontruzant

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Organon LLC
DUNS: 117494753
Effective Date
January 31, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Trastuzumab(150 mg in 1 1)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Samsung Bioepis Co., Ltd.

557822226

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ontruzant

Product Details

NDC Product Code
78206-147
Application Number
BLA761100
Marketing Category
BLA (C73585)
Route of Administration
INTRAVENOUS
Effective Date
January 31, 2023
Code: P188ANX8CKClass: ACTIBQuantity: 150 mg in 1 1
histidine monohydrochloride monohydrateInactive
Code: X573657P6PClass: IACTQuantity: 3.4 mg in 1 1
histidineInactive
Code: 4QD397987EClass: IACTQuantity: 2.2 mg in 1 1
polysorbate 20Inactive
Code: 7T1F30V5YHClass: IACTQuantity: 0.6 mg in 1 1
trehalose dihydrateInactive
Code: 7YIN7J07X4Class: IACTQuantity: 136.2 mg in 1 1

Ontruzant

Product Details

NDC Product Code
78206-148
Application Number
BLA761100
Marketing Category
BLA (C73585)
Route of Administration
INTRAVENOUS
Effective Date
January 31, 2023

Drug Labeling Information

Complete FDA-approved labeling information including indications, dosage, warnings, contraindications, and other essential prescribing details.

BOXED WARNING SECTION

**WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and

PULMONARY TOXICITY**


© Copyright 2025. All Rights Reserved by MedPath